A Randomized, Placebo-Controlled Trial of Sustained-Release Dextroamphetamine for Treatment of Methamphetamine Addiction. Galloway, G., Buscemi, R, Coyle, J., Flower, K, Siegrist, J., Fiske, L., Baggott, M., Li, L, Polcin, D, Chen, C., & Mendelson, J Clinical Pharmacology & Therapeutics, 89(2):276–282, 2011. _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1038/clpt.2010.307![A Randomized, Placebo-Controlled Trial of Sustained-Release Dextroamphetamine for Treatment of Methamphetamine Addiction [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Sixty treatment-seeking individuals with methamphetamine (MA) dependence entered a randomized, placebo-controlled, double-blind clinical trial of oral dextroamphetamine (d-AMP) as a replacement therapy for MA dependence. The subjects took 60 mg sustained-release d-AMP for 8 weeks, during which time they received eight 50-min sessions of individual psychotherapy. Adverse events and urine toxicology for MA were assessed two times a week. There were no serious adverse events. Urine samples containing \textless1,000 ng/ml of MA were classified as negative for MA. The MA-negative scores in the d-AMP group (3.1 ± SD 4.6) were no higher than those in the placebo group (3.3 ± SD 5.3; P \textgreater 0.05). However, withdrawal and craving scores were significantly lower in the d-AMP group (P \textless 0.05 for both). Although subjects taking d-AMP did not reduce their use of MA, the significant reductions observed in withdrawal and craving scores in this group support the need for further exploration of d-AMP as a pharmacologic intervention for MA dependence, possibly at higher doses. Clinical Pharmacology & Therapeutics (2011) 89 2, 276–282. doi:10.1038/clpt.2010.307
@article{galloway_randomized_2011,
title = {A {Randomized}, {Placebo}-{Controlled} {Trial} of {Sustained}-{Release} {Dextroamphetamine} for {Treatment} of {Methamphetamine} {Addiction}},
volume = {89},
issn = {1532-6535},
url = {https://onlinelibrary.wiley.com/doi/abs/10.1038/clpt.2010.307},
doi = {10.1038/clpt.2010.307},
abstract = {Sixty treatment-seeking individuals with methamphetamine (MA) dependence entered a randomized, placebo-controlled, double-blind clinical trial of oral dextroamphetamine (d-AMP) as a replacement therapy for MA dependence. The subjects took 60 mg sustained-release d-AMP for 8 weeks, during which time they received eight 50-min sessions of individual psychotherapy. Adverse events and urine toxicology for MA were assessed two times a week. There were no serious adverse events. Urine samples containing {\textless}1,000 ng/ml of MA were classified as negative for MA. The MA-negative scores in the d-AMP group (3.1 ± SD 4.6) were no higher than those in the placebo group (3.3 ± SD 5.3; P {\textgreater} 0.05). However, withdrawal and craving scores were significantly lower in the d-AMP group (P {\textless} 0.05 for both). Although subjects taking d-AMP did not reduce their use of MA, the significant reductions observed in withdrawal and craving scores in this group support the need for further exploration of d-AMP as a pharmacologic intervention for MA dependence, possibly at higher doses. Clinical Pharmacology \& Therapeutics (2011) 89 2, 276–282. doi:10.1038/clpt.2010.307},
language = {en},
number = {2},
urldate = {2023-05-25},
journal = {Clinical Pharmacology \& Therapeutics},
author = {Galloway, Gp and Buscemi, R and Coyle, Jr and Flower, K and Siegrist, Jd and Fiske, La and Baggott, Mj and Li, L and Polcin, D and Chen, Cya and Mendelson, J},
year = {2011},
note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1038/clpt.2010.307},
keywords = {Amphetamine},
pages = {276--282},
}
Downloads: 0
{"_id":"hyscpfhYaKDTroFsn","bibbaseid":"galloway-buscemi-coyle-flower-siegrist-fiske-baggott-li-etal-arandomizedplacebocontrolledtrialofsustainedreleasedextroamphetaminefortreatmentofmethamphetamineaddiction-2011","author_short":["Galloway, G.","Buscemi, R","Coyle, J.","Flower, K","Siegrist, J.","Fiske, L.","Baggott, M.","Li, L","Polcin, D","Chen, C.","Mendelson, J"],"bibdata":{"bibtype":"article","type":"article","title":"A Randomized, Placebo-Controlled Trial of Sustained-Release Dextroamphetamine for Treatment of Methamphetamine Addiction","volume":"89","issn":"1532-6535","url":"https://onlinelibrary.wiley.com/doi/abs/10.1038/clpt.2010.307","doi":"10.1038/clpt.2010.307","abstract":"Sixty treatment-seeking individuals with methamphetamine (MA) dependence entered a randomized, placebo-controlled, double-blind clinical trial of oral dextroamphetamine (d-AMP) as a replacement therapy for MA dependence. The subjects took 60 mg sustained-release d-AMP for 8 weeks, during which time they received eight 50-min sessions of individual psychotherapy. Adverse events and urine toxicology for MA were assessed two times a week. There were no serious adverse events. Urine samples containing \\textless1,000 ng/ml of MA were classified as negative for MA. The MA-negative scores in the d-AMP group (3.1 ± SD 4.6) were no higher than those in the placebo group (3.3 ± SD 5.3; P \\textgreater 0.05). However, withdrawal and craving scores were significantly lower in the d-AMP group (P \\textless 0.05 for both). Although subjects taking d-AMP did not reduce their use of MA, the significant reductions observed in withdrawal and craving scores in this group support the need for further exploration of d-AMP as a pharmacologic intervention for MA dependence, possibly at higher doses. Clinical Pharmacology & Therapeutics (2011) 89 2, 276–282. doi:10.1038/clpt.2010.307","language":"en","number":"2","urldate":"2023-05-25","journal":"Clinical Pharmacology & Therapeutics","author":[{"propositions":[],"lastnames":["Galloway"],"firstnames":["Gp"],"suffixes":[]},{"propositions":[],"lastnames":["Buscemi"],"firstnames":["R"],"suffixes":[]},{"propositions":[],"lastnames":["Coyle"],"firstnames":["Jr"],"suffixes":[]},{"propositions":[],"lastnames":["Flower"],"firstnames":["K"],"suffixes":[]},{"propositions":[],"lastnames":["Siegrist"],"firstnames":["Jd"],"suffixes":[]},{"propositions":[],"lastnames":["Fiske"],"firstnames":["La"],"suffixes":[]},{"propositions":[],"lastnames":["Baggott"],"firstnames":["Mj"],"suffixes":[]},{"propositions":[],"lastnames":["Li"],"firstnames":["L"],"suffixes":[]},{"propositions":[],"lastnames":["Polcin"],"firstnames":["D"],"suffixes":[]},{"propositions":[],"lastnames":["Chen"],"firstnames":["Cya"],"suffixes":[]},{"propositions":[],"lastnames":["Mendelson"],"firstnames":["J"],"suffixes":[]}],"year":"2011","note":"_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1038/clpt.2010.307","keywords":"Amphetamine","pages":"276–282","bibtex":"@article{galloway_randomized_2011,\n\ttitle = {A {Randomized}, {Placebo}-{Controlled} {Trial} of {Sustained}-{Release} {Dextroamphetamine} for {Treatment} of {Methamphetamine} {Addiction}},\n\tvolume = {89},\n\tissn = {1532-6535},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1038/clpt.2010.307},\n\tdoi = {10.1038/clpt.2010.307},\n\tabstract = {Sixty treatment-seeking individuals with methamphetamine (MA) dependence entered a randomized, placebo-controlled, double-blind clinical trial of oral dextroamphetamine (d-AMP) as a replacement therapy for MA dependence. The subjects took 60 mg sustained-release d-AMP for 8 weeks, during which time they received eight 50-min sessions of individual psychotherapy. Adverse events and urine toxicology for MA were assessed two times a week. There were no serious adverse events. Urine samples containing {\\textless}1,000 ng/ml of MA were classified as negative for MA. The MA-negative scores in the d-AMP group (3.1 ± SD 4.6) were no higher than those in the placebo group (3.3 ± SD 5.3; P {\\textgreater} 0.05). However, withdrawal and craving scores were significantly lower in the d-AMP group (P {\\textless} 0.05 for both). Although subjects taking d-AMP did not reduce their use of MA, the significant reductions observed in withdrawal and craving scores in this group support the need for further exploration of d-AMP as a pharmacologic intervention for MA dependence, possibly at higher doses. Clinical Pharmacology \\& Therapeutics (2011) 89 2, 276–282. doi:10.1038/clpt.2010.307},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2023-05-25},\n\tjournal = {Clinical Pharmacology \\& Therapeutics},\n\tauthor = {Galloway, Gp and Buscemi, R and Coyle, Jr and Flower, K and Siegrist, Jd and Fiske, La and Baggott, Mj and Li, L and Polcin, D and Chen, Cya and Mendelson, J},\n\tyear = {2011},\n\tnote = {\\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1038/clpt.2010.307},\n\tkeywords = {Amphetamine},\n\tpages = {276--282},\n}\n\n","author_short":["Galloway, G.","Buscemi, R","Coyle, J.","Flower, K","Siegrist, J.","Fiske, L.","Baggott, M.","Li, L","Polcin, D","Chen, C.","Mendelson, J"],"key":"galloway_randomized_2011","id":"galloway_randomized_2011","bibbaseid":"galloway-buscemi-coyle-flower-siegrist-fiske-baggott-li-etal-arandomizedplacebocontrolledtrialofsustainedreleasedextroamphetaminefortreatmentofmethamphetamineaddiction-2011","role":"author","urls":{"Paper":"https://onlinelibrary.wiley.com/doi/abs/10.1038/clpt.2010.307"},"keyword":["Amphetamine"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/tub49573","dataSources":["zdB47AZpEkG3LzPTn"],"keywords":["amphetamine"],"search_terms":["randomized","placebo","controlled","trial","sustained","release","dextroamphetamine","treatment","methamphetamine","addiction","galloway","buscemi","coyle","flower","siegrist","fiske","baggott","li","polcin","chen","mendelson"],"title":"A Randomized, Placebo-Controlled Trial of Sustained-Release Dextroamphetamine for Treatment of Methamphetamine Addiction","year":2011}